Dear All: CARB-X has today announced funding of 7 more companies, bringing the total funded portfolio to 17 potential new therapies (or preventatives) and 1 novel point-of-care diagnostic (see
Dear All: Two things of note this afternoon… First, the previously noted BARDA RFP to acquire biothreat antibiotics is now posted here with submissions accepted through 21 June 2019: “Under this RFP,
Dear All, Committing serial email this afternoon… First, the note I just sent on FMT for Clostridium difficile (link) prompted comments that the organism is now called Clostridioides difficile.
Dear All: CARB-X is looking for you! This new job was just now posted: The Director of R&D is a new senior role on the leadership team of
Dear All: Two interesting job posts this week. Could one of them be for you? First, CARB-X seeks a Boston-based full-time Chief of R&D (link). This
Dear All: The Cystic Fibrosis Foundation (CFF) has a standing list of funding opportunities (link), including an annual cycle to fund new therapeutics (link). CFF
Aside: There is now an application link for the Mar 2020 Antibacterial R&D GRC meeting. See calendar listing below my signature! Dear All: CARB-X this
Dear All, Two things on a Friday afternoon: First,CARB-X Funding Round 4 will be open from 12-19 Nov 2019 for Expressions of Interest (EOIs). This round
Dear All: Just in case you missed the 30 March annoucement, see at right a snapshot of the first 11 Powered by CARB-X funded companies. Initial funding is